STOCK TITAN

Enveric Biosciences Inc - ENVB STOCK NEWS

Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.

Enveric Biosciences Inc (ENVB) is a biotechnology innovator developing neuroplastogenic therapies for mental health disorders. This page serves as the definitive source for all company announcements, research milestones, and industry developments.

Access real-time updates on clinical trials, regulatory progress, and strategic partnerships. Investors will find curated press releases covering therapeutic advancements like EB-003's neuroplasticity mechanisms and EB-002's prodrug technology, alongside financial disclosures and executive insights.

Our news collection prioritizes accuracy and timeliness, offering:

• Clinical development updates
• Regulatory pathway announcements
• Peer-reviewed research highlights
• Strategic collaboration news

Bookmark this page for streamlined tracking of ENVB's progress in creating non-hallucinogenic psychiatric treatments. Verify information directly through primary sources via provided documentation links when available.

Rhea-AI Summary

Enveric Biosciences (ENVB) has appointed Dr. Arash Asher, Director of Cancer Rehabilitation at Cedars-Sinai, to its Scientific Advisory Board. Dr. Asher's expertise in managing chemotherapy-related side effects is expected to enhance the development of cannabinoid therapies aimed at improving cancer patients' quality of life. This appointment follows the board's first meeting on April 25, 2021, where they discussed clinical development plans for radiodermatitis and glioblastoma, emphasizing support for ongoing cannabinoid research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
management
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ:ENVB) announced that CEO David Johnson will present at the Planet MicroCap Showcase on April 21, 2021, at 9:00 a.m. ET. This virtual event aims to highlight the company's innovative cannabinoid medicines designed for cancer patients, particularly addressing issues like radiodermatitis and chemotherapy-induced neuropathy. Interested participants can register for the live presentation and access additional conference details through provided links. The company's commitment to patient-first solutions is emphasized throughout the announcement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
conferences
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on cannabinoid medicines for cancer patients, announced the appointment of Carter Ward as Chief Financial Officer effective May 15, 2021. He replaces John Van Buiten, who will continue in a consulting role. Mr. Ward brings over 30 years of experience in life sciences and capital markets. His prior role was CFO at Elite Pharmaceuticals, where he led successful capital raises and financial initiatives. Enveric has made strategic progress since going public in late December 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.45%
Tags
management
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) reported its financial results for the year ending December 31, 2020, alongside updates on its 2021 progress. The company secured approximately $22.8 million in gross proceeds through two direct offerings, enabling accelerated research on cannabinoid therapies for cancer patients. Enveric acquired exclusive licenses for five molecules targeting pain and dermatology and entered a collaboration with PureForm. They aim to initiate pivotal clinical trials in supportive care markets, including glioblastoma and radiation dermatitis, in 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) announced the appointment of Dr. Douglas D. Lind to its board of directors on March 18, 2021. Dr. Lind brings over 30 years of experience in healthcare and finance, having worked as a physician and a senior equity research analyst. He co-founded Biomark Capital, focusing on ventures in oncology and medical imaging. CEO Dave Johnson expressed confidence that Dr. Lind's diverse background will contribute significantly to enhancing treatment options for cancer patients, especially in managing side effects from therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
management
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ:ENVB), a biotechnology firm focused on cannabinoid medicines for cancer patients, discussed its recent acquisition of an exclusive license from Diverse Biotech in a video interview with CEO David Johnson. This strategic move aims to develop new treatments for conditions like radiodermatitis and chemotherapy-induced neuropathy. Enveric is dedicated to improving patient quality of life through rigorously tested innovations. The company continues to highlight its commitment to the cancer patient community through these advancements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Diverse Biotech has finalized a strategic transaction with Enveric Biosciences, granting exclusive global rights to develop and commercialize five novel compounds targeting adverse side effects from cancer treatments. The deal includes an undisclosed upfront payment and future royalties on sales. Diverse Biotech utilizes a sophisticated drug discovery platform, leveraging cannabinoids to create new drug candidates that may offer enhanced efficacy and reduced side effects compared to current therapies. This collaboration aims to expedite the availability of these treatments for oncology patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
none
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) announced that CEO David Johnson will speak at two virtual investor conferences in March 2021. The first is the M Vest and Maxim Group Emerging Growth Conference on March 18, 2021, and the second is the Benzinga Biotech Small Cap Conference on March 25, 2021, where he will present at 12:30 p.m. ET and participate in a panel discussion at 11:40 a.m. ET. The company focuses on developing cannabinoid medicines aimed at improving cancer patients' quality of life, addressing conditions like radiodermatitis and chemotherapy-induced neuropathy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
conferences
-
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) has acquired an exclusive, perpetual license from Diverse Biotech to develop cannabinoid medicines aimed at improving the quality of life for cancer patients. The agreement involves five new drug molecules, enhancing Enveric's pipeline with four dermatology-focused and one pain-focused compound. This partnership is expected to leverage Diverse Biotech's patented drug delivery platform to combine CBD with existing treatments, targeting side effects of cancer therapies. Enveric aims to address unmet medical needs and expand its intellectual property portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
54.95%
Tags
Rhea-AI Summary

Enveric Biosciences (NASDAQ: ENVB) has announced a strategic development collaboration and exclusive supply agreement with PureForm Global, Inc. This partnership aims to develop cannabinoid medicines that alleviate treatment side effects for cancer patients. PureForm will be Enveric's exclusive supplier of synthetic, non-cannabis-based CBD, with plans targeting conditions like radiodermatitis and chemotherapy-induced neuropathy. The agreement ensures a consistent supply of high-quality CBD for clinical studies and emphasizes rigorous scientific research to enhance treatment options for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.71%
Tags
none
Enveric Biosciences Inc

Nasdaq:ENVB

ENVB Rankings

ENVB Stock Data

2.89M
2.47M
0.07%
7.16%
64.5%
Biotechnology
Pharmaceutical Preparations
Link
United States
NAPLES